Special Segment: Soft Tissue Matrices— Apligraf Bilayered Skin Substitute to Augment Healing of Chronic Wounds in Diabetic Patients

Abstract

Chronic wounds are wounds that fail to heal or fail to progress to healing within an appropriate time frame. Standard wound care consists of debridement of all nonviable tissue, off-loading, and maintaining a moist environment, typically with saline-moistened gauze. Infection control, blood flow, and nutrition also play pivotal roles in wound healing. Bioengineered tissue, Apligraf, has been shown to be both efficacious and safe when used in chronic wounds. Apligraf delivers growth factors and cytokines to the wound environment to help complete closure and decrease healing time.

Keywords

Apligraf bioengineered tissue autograft tissue engineering diabetic foot ulcers

Get full access to this article

View all access options for this article.

References

Kirsner RS , Falanga V. , Eaglstein WH The development of bioengineered skin. Trends Biotechnol . 1998;16:249-249.

Dinh TL , Veves A. The efficacy of Apligraf in the treatment of diabetic foot ulcers . Plast Reconstr Surg. 2006;117(7 suppl):152S-157S.

Mayfield JA , Reiber GE , Sanders LJ , Janisse D. , Pogach LM Preventive foot care in people with diabetes. Diabetes Care . 1998;21:2161-2177.

Palumbo PJ , Melton LJ III. Peripheral vascular disease and diabetes. In: Diabetes in America: Diabetes Data Complied 1984. (NIH publication no. 85-1468). Washington, DC: Government Printing Office; 1985:XV-1-XV-21.

Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999 , Boston, Massachusetts. Diabetes Care. 1999;22:1354-1360.

Singh N. , Armstong DG , Lipsky BA Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217-228.

Boulton AJM , Vileikyte L. , Ragnarson-Tennvall G. , Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366:1719-1724.

Reiber GE , Vileikyte L. , Boyko EJ , et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999;22:157-162.

Boulton AJM , Kirsner RS , Vileikyte L. Neuropathic diabetic foot ulcers. N Engl J Med. 2004;351:48-55.

10.

Zacur H. , Kirsner RS Debridement: rationale and therapeutic options. Wounds . 2002;14(suppl E):2E-7E.

11.

Mueller MJ , Diamond JE , Sinacore DR , et al. Total contact casting in treatment of diabetic plantar ulcers: controlled clinical trial. Diabetes Care. 1989;12:384-388.

12.

Armstrong DG , Nguyen HC , Lavery LA , Van Schie CH , Boulton AJM , Harkless LB Off-loading the diabetic foot wound: a randomized clinical trial [published correction appears in Diabetes Care. 2001;24:1509]. Diabetes Care. 2001;24:1019-1022.

13.

Lipsky BA , Berendt AR Principles and practice of antibiotic therapy of diabetic foot infections . Diabetes Metab Res Rev. 2000;16(suppl 1):S42-S46.

14.

Veves A. , Falanga V. , Armstrong DG , Sabolinski ML Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers. Diabetes Care. 2001;24:290-295.

15.

Sams HH , Chen J. , Kin LE Graftskin treatment of difficult to heal diabetic foot ulcers: one center’s experience. Dermatol Surg. 2002;28:698-703.

16.

Brem H. , Balledux J. , Bloom T. , Kerstein MD , Hollier L. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg. 2000;135:627-634.

17.

Espensen EH , Nicon BP , Lavery LA , Armstrong DG Use of subatmospheric (VAC) therapy to improve bioengineered tissue grafting in diabetic foot wounds . J Am Podiatr Med Assoc. 2002;92:395-397.

18.

Edmonds M. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds. 2009;(8)1:11-18.